Fabrication and Evaluation of Colon Targeted Uricase Containing Microbeads for Treatment of Gout

Dwivedi, Harinath; Agarwal, Kusum Lata; Saraf, Shubhini A.

doi:10.2174/2210304x11303010007

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, colonic drug delivery is not only used for localized treatment of gut diseases, but also for oral delivery of protein therapeutics, which are acid labile and enzyme degradable, to protect these therapeutics from the harsh gastrointestinal conditions preceding the absorption process [21]. For example, uricase, an enzyme responsible for breaking down urate crystals accumulated in body joints, was encapsulated into alginate/pectin microparticles for the treatment of gout [22]. These microparticles were coated with a pH-responsive polymer (Eudragit S-100) to protect the protein (uricase) from degradation by gastric enzymes, where this system displayed enhanced colonic absorption when the drug was combined with bile salts.…”

Section: Introductionmentioning

confidence: 99%

Smart Pellets for Controlled Delivery of 5-Fluorouracil

et al. 2022

View full text Add to dashboard Cite

This work aimed to develop a new one-pot and readily scaled-up formulation capable of retaining 5-fluorouracil and prolonging its release to obtain a site-specific medication delivery for the potential treatment of colorectal cancer. Six polymer-based formulations were successfully produced using a thermal bulk polymerization method and loaded with 5-fluorouracil, which is a chemotherapeutic agent used in the treatment of colorectal carcinoma. The pellets produced were characterized by measuring the glass transition temperature, tensile strength, Young’s modulus, and tensile elongation at break. Studies on in vitro swelling and release were carried out in phosphate-buffered saline to evaluate the behaviour of the developed system. The Young’s modulus, glass transition temperature, and tensile strength all increased significantly as the crosslinker concentration increased, but the fracture strain value reduced significantly. The in vitro swelling profile of the produced formulations was significantly reduced by increasing crosslinking density. Less than 27% cumulative drug release was achieved for all formulations after 5 h of starting the release study. The highest cumulative drug release reached after 24 h was 69%. The developed drug delivery system demonstrated the ability to delay the release of 5-fluorouracil in upper gastrointestinal tract-mimicking conditions, while permitting its release in a controlled way afterward, which makes it promising for the potential delivery of 5-fluorouracil to the colon.

show abstract

Section: Introductionmentioning

confidence: 99%